Twist Bioscience Stock Soars After Q3 Report - Here's Why
Portfolio Pulse from Vandana Singh
Twist Bioscience Corp (NASDAQ:TWST) reported Q3 sales of $63.7 million, a 14% increase Y/Y, beating the consensus of $60.71 million. The company also reported a Q3 EPS loss of $(1.01), better than the consensus of $(1.14). The company raised its FY23 revenue guidance to $241-$242 million, up from the previous guidance of $235-$238 million. The company's shares are up 13.7% at $23.50.
August 04, 2023 | 3:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Twist Bioscience's Q3 sales beat consensus and the company raised its FY23 revenue guidance. The company's shares are up 13.7%.
Twist Bioscience reported better than expected Q3 results and raised its FY23 revenue guidance, which is likely to have a positive impact on investor sentiment and the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100